All News

Our quest to make sense of a complex future data ecosystem in pharma.

A look at highlights from the Digital Pharma East conference looking at technology and marketing innovation in pharma.

Leela Barham reacts to the Institute for Economic and Clinical Review's very first Unsupported Price Increase (UPI) report.

Click the title above to open the Pharmaceutical Executive October 2019 issue in an interactive PDF format.

After two decades of building a robust healthcare ecosystem, Thailand is seeking to move to the next level-Thailand 4.0-a potential stepping stone in its strategy to initiate a transformative era with a greater embrace of R&D.

A look into how native advertising works, what cost benefits they provide, and measuring their success.

As patients pay more healthcare expenses directly from their own pockets, the industry must look at patients' ability to pay alongside willingness to pay to understand the various factors of patient decisions to accept or decline treatment.

Click the title above to open the Pharmaceutical Executive September 2019 issue in an interactive PDF format.

A decade into China’s far-reaching healthcare reforms-which began with the implementation of universal, albeit rudimentary, medical insurance-the pace of change and transformation within the country’s life sciences industry shows no signs of abating.

The latest trends in patent litigation has led to a more harmonized patent system, which can benefit pharmaceutical companies that invest in patents.

Every healthcare company should be striving to identify better ways to ensure patients and consumers inspire every decision they make, writes Joanne Waldstreicher.

Do’s and Dont’s while facing the increased war for talent.

A 2019 study reveals further marginal decline in the pharma industry's reputation. Sven Klingemann suggests some "recovery solutions".

A look at questions that need to be answered regarding drug importation coexisting with the Drug Supply Chain Security Act (DSCSA).